CD8A and neoplasm: In combination with anti-PD-L1 therapy, SatVax markedly increased the frequency of E7-specific CD8+ T cells, while reducing the proportion of exhausted phenotypes (CD8+Tim3+ and CD8+PD-1+), leading to complete tumor clearance in four out of five treated mice [86].